Chinese innovative drug stocks rise against the trend; Jinling Pharmaceutical hits 2nd limit-up

The move stands out less for its size than for its direction: innovative drug names advancing while the broader market slips suggests money is rotating into the sector on its own narrative rather than riding general risk appetite. That the gains cluster across large and small caps — from a second straight limit-up to broad 5%+ moves — points to sector-wide interest rather than a single stock story. Whether this decoupling from the wider market persists, or proves a one-session rotation, is the open question worth watching.